Achieve Life Sciences to Unveil Long-Term Cytisinicline Efficacy…

Event summary

Achieve Life Sciences will present 52-week efficacy data for cytisinicline in smoking and e-cigarette cessation at CHEST 2026 on October 20, 2026.
The ORCA-OL trial enrolled 475 adults who received cytisinicline 3 mg three times daily for 52 weeks.
The study evaluated biochemically verified abstinence rates throughout the treatment period.
Cytisinicline has received Breakthrough Therapy designation from the FDA for e-cigarette cessation.

The big picture

Achieve Life Sciences' presentation at CHEST 2026 comes at a critical juncture for the nicotine cessation market, which remains underserved despite the high prevalence of smoking and vaping. The company's focus on long-term efficacy data aligns with growing regulatory and consumer demand for effective, sustained treatments. The strategic significance lies in cytisinicline's potential to address both combustible cigarette and e-cigarette addiction, a dual-market opportunity that could differentiate it from existing therapies.

What we're watching

Regulatory Pathway: Whether the FDA will expedite the approval process for cytisinicline given its Breakthrough Therapy designation.
Market Potential: The pace at which Achieve Life Sciences can commercialize cytisinicline for both smoking and e-cigarette cessation.
Clinical Efficacy: How the long-term efficacy data from the ORCA-OL trial will impact investor confidence and potential partnerships.